Jonathan Solomon

Jonathan Solomon is Director of Chemical Genetics at Novartis Biomedical Research and has spent more than a decade advancing targeted protein degradation and molecular glue discovery. He has contributed to landmark discoveries including the DCAF15-indisulam-RBM39 ternary complex, CRBN molecular glues targeting Helios and WIZ, and the first VHL molecular glue degrader targeting CDO1. His research focuses on identifying novel molecular glue starting points and translating degraders into therapeutics.